ABP-745 / Hangzhou Atom Therapeutics - LARVOL DELTA

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Atom Therapeutics Co., Ltd | Trial completion date: Jul 2028 ➔ Apr 2028

Trial completion date • Atherosclerosis • Cardiovascular

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Atom Therapeutics Co., Ltd

New P2 trial • Atherosclerosis • Cardiovascular

A Phase 1 Placebo Controlled, Single (SAD) and Multiple Dose Escalation (MAD) Safety and Pharmacokinetic (PK) Study of a Novel Colchicine Analogue ABP-745 in Healthy Volunteers (HV) (ACR Convergence 2025) - "Safety and pharmacokinetics (PK) of ABP-745 following single, and multiple qd and bid oral doses in healthy volunteers under fasted and fed conditions further supports development of ABP-745 in an acute gout indication."

Clinical • P1 data • PK/PD data • Constipation • Gastroenterology • Gastrointestinal Disorder • Gout • Inflammatory Arthritis • Rheumatology

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare (clinicaltrials.gov) - P2 | N=380 | Recruiting | Sponsor: Atom Therapeutics Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Gout • Immunology • Inflammatory Arthritis • Rheumatology

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare (clinicaltrials.gov) - P2 | N=380 | Not yet recruiting | Sponsor: Atom Therapeutics Co., Ltd

New P2 trial • Gout • Immunology • Inflammatory Arthritis • Rheumatology

ABP-745-101: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.

New P1 trial • Gout • Inflammatory Arthritis • Rheumatology